Dr. Bing Yao is the CEO of Viela Bio, a spinoff from MedImmune. He has 20 years’ experience in the biopharmaceutical industry, with a track record of leading successful discovery and development of multiple biotherapeutics. He has served in key leadership roles in and lent critical contribution to the development and approval of multiple biologic products including: IMFINZI, FASENRA, and Siliq.
Previously, Dr. Yao has served as the SVP of MedImmune, Head of Respiratory, Inflammation and Autoimmune and the Former Head of Immuno-oncology Franchise of AstraZeneca. In addition, he has former leadership roles with Genentech and Tanox.